Europe Active Pharmaceutical Ingredients (API) Market 2020-2026 by Synthesis (Synthetic, Biotech, HPAPI), Manufacturing Process (Captive, Merchant), Therapeutic Application, Drug Type, and Country: Trend Forecast and Growth Opportunity

133 pages | Grace Market Data
Europe active pharmaceutical ingredients (API) market reached $42.41 billion in 2019 and will grow by 7.6% annually over 2020-2026 owing to the rising need for medicine and pharmaceutical agents amid the COVID-19 pandemic.
Highlighted with 41 tables and 66 figures, this 133-page report “Europe Active Pharmaceutical Ingredients (API) Market 2020-2026 by Synthesis (Synthetic, Biotech, HPAPI), Manufacturing Process (Captive, Merchant), Therapeutic Application, Drug Type, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe API market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2026 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe API market in every aspect of the classification from perspectives of Synthesis, Manufacturing Process, Therapeutic Application, Drug Type, and Country.

Based on Synthesis, the Europe market is segmented into the following sub-markets with annual revenue for 2015-2026 included in each section.
Synthetic API
• Branded Synthetic API
• Generic Synthetic API
Biotech API by Drug Type:
• Monoclonal Antibodies
• Recombinant Proteins
• Vaccines
• Other Biotech APIs
Biotech API by Customer Base:
• Innovative Biologic API
• Generic Biosimilar API
Biotech API by Expression Technology:
• Mammalian Expression
• Microbial Expression
• Yeast Expression
• Insect Expression
• Other Expression Technologies
HPAPI
• Branded HPAPI
• Generic HPAPI

Based on Manufacturing Process, the Europe market is segmented into the following sub-markets with annual revenue for 2015-2026 included in each section.
Captive Manufacturing
• Branded Captive API
• Generic Captive API
Merchant Manufacturing by Drug Type:
• Branded Merchant API
• Generic Merchant API
Merchant Manufacturing by Drug Synthesis:
• Merchant Synthetic API
• Merchant Biotech API

Based on Therapeutic Application, the Europe market is segmented into the following sub-markets with annual revenue for 2015-2026 included in each section.
• Infectious Diseases
• Oncology
• Ophthalmology
• Cardiovascular Disorders
• Central Nervous System
• Pulmonary Disorders
• Orthopedics
• Other Applications

Based on Drug Type, the Europe market is segmented into the following sub-markets with annual revenue for 2015-2026 included in each section.
• Branded Prescription Drugs
• Generic Prescription Drugs
• OTC Drugs

Geographically, the following national/local markets are fully investigated:
• Germany
• UK
• France
• Spain
• Italy
• Russia
• Rest of Europe (further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania)
For each aforementioned country, detailed analysis and data for annual revenue are available for 2015-2026. The breakdown of key national markets by Synthesis, Manufacturing Process, and Therapeutic Application over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in Europe API market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
AbbVie Inc.
Astrazeneca
Aurobindo Pharma Ltd.
Bayer Healthcare
Bioniche Animal Health
Boehringer Ingelheim
Bristol-Myers Squibb
Ceva Animal Health, Inc.
Elanco Animal Health
Eli Lilly and Company
F. Hoffmann-La Roche
Glaxosmithkline PLC
Heska Co.
Lonza Group
Merck & Co., Inc.
Novartis International AG
Pfizer, Inc.
Ranbaxy Laboratories
Sanofi
Sun Pharmaceutical Industries Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
1 Introduction 7

1.1 Industry Definition and Research Scope 7

1.1.1 Industry Definition 7

1.1.2 Research Scope 8

1.2 Research Methodology 11

1.2.1 Overview of Market Research Methodology 11

1.2.2 Market Assumption 12

1.2.3 Secondary Data 12

1.2.4 Primary Data 12

1.2.5 Data Filtration and Model Design 14

1.2.6 Market Size/Share Estimation 15

1.2.7 Research Limitations 16

1.3 Executive Summary 17

2 Market Overview and Dynamics 19

2.1 Market Size and Forecast 19

2.2 Major Growth Drivers 20

2.3 Market Restraints and Challenges 24

2.4 Emerging Opportunities and Market Trends 27

2.5 Porter’s Fiver Forces Analysis 31

3 Segmentation of Europe Market by Synthesis 35

3.1 Market Overview by Synthesis 35

3.2 Synthetic API 37

3.2.1 Branded Synthetic API 38

3.2.2 Generic Synthetic API 39

3.3 Biotech API 40

3.3.1 Biotech API by Drug Type 41

3.3.1.1 Monoclonal Antibodies 42

3.3.1.2 Recombinant Proteins 43

3.3.1.3 Vaccines 44

3.3.1.4 Other Biotech APIs 45

3.3.2 Biotech API by Customer Base 46

3.3.2.1 Innovative Biologic API 47

3.3.2.2 Generic Biosimilar API 48

3.3.3 Biotech API by Expression Technology 49

3.3.3.1 Mammalian Expression 50

3.3.3.2 Microbial Expression 51

3.3.3.3 Yeast Expression 52

3.3.3.4 Insect Expression 53

3.3.3.5 Other Expression Technologies 54

3.4 HPAPI 55

3.4.1 Branded HPAPI 56

3.4.2 Generic HPAPI 57

4 Segmentation of Europe Market by Manufacturing Process 58

4.1 Market Overview by Manufacturing Process 58

4.2 Captive Manufacturing 60

4.2.1 Branded Captive API 61

4.2.2 Generic Captive API 62

4.3 Merchant Manufacturing 63

4.3.1 Merchant Manufacturing by Drug Type 64

4.3.1.1 Branded Merchant API 65

4.3.1.2 Generic Merchant API 66

4.3.2 Merchant Manufacturing by Drug Synthesis 67

4.3.2.1 Merchant Synthetic API 68

4.3.2.2 Merchant Biotech API 69

5 Segmentation of Europe Market by Therapeutic Application 70

5.1 Market Overview by Therapeutic Application 70

5.2 Infectious Diseases 72

5.3 Oncology 73

5.4 Ophthalmology 74

5.5 Cardiovascular Disorders 75

5.6 Central Nervous System 76

5.7 Pulmonary Disorders 77

5.8 Orthopedics 78

5.9 Other Applications 79

6 Segmentation of Europe Market by Drug Type 80

6.1 Market Overview by Drug Type 80

6.2 Branded Prescription Drugs 82

6.3 Generic Prescription Drugs 83

6.4 OTC Drugs 84

7 European Market 2019-2026 by Country 85

7.1 Overview of European Market 85

7.2 UK 88

7.3 France 90

7.4 Germany 92

7.5 Spain 94

7.6 Italy 96

7.7 Russia 98

7.8 Rest of European Market 100

8 Competitive Landscape 102

8.1 Overview of Key Vendors 102

8.2 New Product Launch, Partnership, Investment, and M&A 105

8.3 Company Profiles 106

AbbVie Inc. 106

Astrazeneca 108

Aurobindo Pharma Ltd. 109

Bayer Healthcare 110

Bioniche Animal Health 111

Boehringer Ingelheim 112

Bristol-Myers Squibb 113

Ceva Animal Health, Inc. 114

Elanco Animal Health 115

Eli Lilly and Company 116

F. Hoffmann-La Roche 117

Glaxosmithkline PLC 118

Heska Co. 119

Lonza Group 120

Merck & Co., Inc. 121

Novartis International AG 122

Pfizer, Inc. 123

Ranbaxy Laboratories 124

Sanofi 125

Sun Pharmaceutical Industries Ltd. 126

9 Investing in Europe Market: Risk Assessment and Management 127

9.1 Risk Evaluation of Europe Market 127

9.2 Critical Success Factors (CSFs) 130

Related Reports and Products 133



Table 1. Snapshot of Europe Active Pharmaceutical Ingredients (API) Market, 2019-2026 18

Table 2. Main Product Trends and Market Opportunities in Europe Active Pharmaceutical Ingredients (API) Market 27

Table 3. Europe Active Pharmaceutical Ingredients (API) Market by Synthesis, 2015-2026, $ bn 35

Table 4. Europe Active Pharmaceutical Ingredients (API) Market: Synthetic API by Drug Type, 2015-2026, $ bn 37

Table 5. Europe Active Pharmaceutical Ingredients (API) Market: Biotech API by Drug Type, 2015-2026, $ bn 41

Table 6. Europe Active Pharmaceutical Ingredients (API) Market: Biotech API by Customer Base, 2015-2026, $ bn 46

Table 7. Europe Active Pharmaceutical Ingredients (API) Market: Biotech API by Expression Technology, 2015-2026, $ bn 49

Table 8. Europe Active Pharmaceutical Ingredients (API) Market: HPAPI by Drug Type, 2015-2026, $ bn 55

Table 9. Europe Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2015-2026, $ bn 58

Table 10. Europe Active Pharmaceutical Ingredients (API) Market: Captive Manufacturing by Drug Type, 2015-2026, $ bn 60

Table 11. Europe Active Pharmaceutical Ingredients (API) Market: Merchant Manufacturing by Drug Type, 2015-2026, $ bn 64

Table 12. Europe Active Pharmaceutical Ingredients (API) Market: Merchant Manufacturing by Drug Synthesis, 2015-2026, $ bn 67

Table 13. Europe Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2015-2026, $ bn 70

Table 14. Europe Active Pharmaceutical Ingredients (API) Market by Drug Type, 2015-2026, $ bn 80

Table 15. Europe Active Pharmaceutical Ingredients (API) Market by Country, 2015-2026, $ bn 87

Table 16. UK Active Pharmaceutical Ingredients (API) Market by Synthesis, 2015-2026, $ bn 89

Table 17. UK Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2015-2026, $ bn 89

Table 18. UK Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2015-2026, $ bn 89

Table 19. France Active Pharmaceutical Ingredients (API) Market by Synthesis, 2015-2026, $ bn 91

Table 20. France Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2015-2026, $ bn 91

Table 21. France Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2015-2026, $ bn 91

Table 22. Germany Active Pharmaceutical Ingredients (API) Market by Synthesis, 2015-2026, $ bn 93

Table 23. Germany Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2015-2026, $ bn 93

Table 24. Germany Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2015-2026, $ bn 93

Table 25. Spain Active Pharmaceutical Ingredients (API) Market by Synthesis, 2015-2026, $ bn 95

Table 26. Spain Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2015-2026, $ bn 95

Table 27. Spain Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2015-2026, $ bn 95

Table 28. Italy Active Pharmaceutical Ingredients (API) Market by Synthesis, 2015-2026, $ bn 97

Table 29. Italy Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2015-2026, $ bn 97

Table 30. Italy Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2015-2026, $ bn 97

Table 31. Russia Active Pharmaceutical Ingredients (API) Market by Synthesis, 2015-2026, $ bn 99

Table 32. Russia Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2015-2026, $ bn 99

Table 33. Russia Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2015-2026, $ bn 99

Table 34. Active Pharmaceutical Ingredients (API) Market in Rest of Europe by Country, 2015-2026, $ bn 101

Table 35. AbbVie Inc.: Company Snapshot 106

Table 36. AbbVie Inc.: Business Segmentation 106

Table 37. AbbVie Inc.: Product Portfolio 107

Table 38. AbbVie Inc.: Revenue, 2016-2018, $ bn 107

Table 39. AbbVie Inc.: Recent Developments 107

Table 40. Risk Evaluation for Investing in Europe Market, 2019-2026 128

Table 41. Critical Success Factors and Key Takeaways 131



Figure 1. Research Method Flow Chart 11

Figure 2. Breakdown of Primary Research 13

Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 15

Figure 4. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2026 17

Figure 5. Europe Active Pharmaceutical Ingredients (API) Market, 2019-2026, $ bn 19

Figure 6. Primary Drivers and Impact Factors of Europe Active Pharmaceutical Ingredients (API) Market 20

Figure 7. GDP per capita in the World, 1960-2018, $ thousand 23

Figure 8. Forecast of Middle-class Population by Region, 2015-2030, million 23

Figure 9. Primary Restraints and Impact Factors of Europe Active Pharmaceutical Ingredients (API) Market 24

Figure 10. Investment Opportunity Analysis 28

Figure 11. Porter’s Fiver Forces Analysis of Europe Active Pharmaceutical Ingredients (API) Market 31

Figure 12. Breakdown of Europe Active Pharmaceutical Ingredients (API) Market by Synthesis, 2019-2026, % of Revenue 35

Figure 13. Contribution to Europe 2020-2026 Cumulative Revenue by Synthesis, Value ($ bn) and Share (%) 36

Figure 14. Europe Active Pharmaceutical Ingredients (API) Market: Synthetic API, 2015-2026, $ bn 37

Figure 15. Europe Active Pharmaceutical Ingredients (API) Market: Branded Synthetic API, 2015-2026, $ bn 38

Figure 16. Europe Active Pharmaceutical Ingredients (API) Market: Generic Synthetic API, 2015-2026, $ bn 39

Figure 17. Europe Active Pharmaceutical Ingredients (API) Market: Biotech API, 2015-2026, $ bn 40

Figure 18. Europe Active Pharmaceutical Ingredients (API) Market: Monoclonal Antibodies, 2015-2026, $ bn 42

Figure 19. Europe Active Pharmaceutical Ingredients (API) Market: Recombinant Proteins, 2015-2026, $ bn 43

Figure 20. Europe Active Pharmaceutical Ingredients (API) Market: Vaccines, 2015-2026, $ bn 44

Figure 21. Europe Active Pharmaceutical Ingredients (API) Market: Other Biotech APIs, 2015-2026, $ bn 45

Figure 22. Europe Active Pharmaceutical Ingredients (API) Market: Innovative Biologic API, 2015-2026, $ bn 47

Figure 23. Europe Active Pharmaceutical Ingredients (API) Market: Generic Biosimilar API, 2015-2026, $ bn 48

Figure 24. Europe Active Pharmaceutical Ingredients (API) Market: Mammalian Expression, 2015-2026, $ bn 50

Figure 25. Europe Active Pharmaceutical Ingredients (API) Market: Microbial Expression, 2015-2026, $ bn 51

Figure 26. Europe Active Pharmaceutical Ingredients (API) Market: Yeast Expression, 2015-2026, $ bn 52

Figure 27. Europe Active Pharmaceutical Ingredients (API) Market: Insect Expression, 2015-2026, $ bn 53

Figure 28. Europe Active Pharmaceutical Ingredients (API) Market: Other Expression Technologies, 2015-2026, $ bn 54

Figure 29. Europe Active Pharmaceutical Ingredients (API) Market: HPAPI, 2015-2026, $ bn 55

Figure 30. Europe Active Pharmaceutical Ingredients (API) Market: Branded HPAPI, 2015-2026, $ bn 56

Figure 31. Europe Active Pharmaceutical Ingredients (API) Market: Generic HPAPI, 2015-2026, $ bn 57

Figure 32. Breakdown of Europe Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2019-2026, % of Revenue 58

Figure 33. Contribution to Europe 2020-2026 Cumulative Revenue by Manufacturing Process, Value ($ bn) and Share (%) 59

Figure 34. Europe Active Pharmaceutical Ingredients (API) Market: Captive Manufacturing, 2015-2026, $ bn 60

Figure 35. Europe Active Pharmaceutical Ingredients (API) Market: Branded Captive API, 2015-2026, $ bn 61

Figure 36. Europe Active Pharmaceutical Ingredients (API) Market: Generic Captive API, 2015-2026, $ bn 62

Figure 37. Europe Active Pharmaceutical Ingredients (API) Market: Merchant Manufacturing, 2015-2026, $ bn 63

Figure 38. Europe Active Pharmaceutical Ingredients (API) Market: Branded Merchant API, 2015-2026, $ bn 65

Figure 39. Europe Active Pharmaceutical Ingredients (API) Market: Generic Merchant API, 2015-2026, $ bn 66

Figure 40. Europe Active Pharmaceutical Ingredients (API) Market: Merchant Synthetic API, 2015-2026, $ bn 68

Figure 41. Europe Active Pharmaceutical Ingredients (API) Market: Merchant Biotech API, 2015-2026, $ bn 69

Figure 42. Breakdown of Europe Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2019-2026, % of Revenue 70

Figure 43. Contribution to Europe 2020-2026 Cumulative Revenue by Therapeutic Application, Value ($ bn) and Share (%) 71

Figure 44. Europe Active Pharmaceutical Ingredients (API) Market: Infectious Diseases, 2015-2026, $ bn 72

Figure 45. Europe Active Pharmaceutical Ingredients (API) Market: Oncology, 2015-2026, $ bn 73

Figure 46. Europe Active Pharmaceutical Ingredients (API) Market: Ophthalmology , 2015-2026, $ bn 74

Figure 47. Europe Active Pharmaceutical Ingredients (API) Market: Cardiovascular Disorders, 2015-2026, $ bn 75

Figure 48. Europe Active Pharmaceutical Ingredients (API) Market: Central Nervous System, 2015-2026, $ bn 76

Figure 49. Europe Active Pharmaceutical Ingredients (API) Market: Pulmonary Disorders, 2015-2026, $ bn 77

Figure 50. Europe Active Pharmaceutical Ingredients (API) Market: Orthopedics, 2015-2026, $ bn 78

Figure 51. Europe Active Pharmaceutical Ingredients (API) Market: Other Applications, 2015-2026, $ bn 79

Figure 52. Breakdown of Europe Active Pharmaceutical Ingredients (API) Market by Drug Type, 2019-2026, % of Revenue 80

Figure 53. Contribution to Europe 2020-2026 Cumulative Revenue by Drug Type, Value ($ bn) and Share (%) 81

Figure 54. Europe Active Pharmaceutical Ingredients (API) Market: Branded Prescription Drugs, 2015-2026, $ bn 82

Figure 55. Europe Active Pharmaceutical Ingredients (API) Market: Generic Prescription Drugs, 2015-2026, $ bn 83

Figure 56. Europe Active Pharmaceutical Ingredients (API) Market: OTC Drugs, 2015-2026, $ bn 84

Figure 57. Breakdown of European Active Pharmaceutical Ingredients (API) Market by Country, 2019 and 2026, % of Revenue 86

Figure 58. Contribution to Europe 2020-2026 Cumulative Revenue by Country, Value ($ bn) and Share (%) 87

Figure 59. Active Pharmaceutical Ingredients (API) Market in UK, 2015-2026, $ bn 88

Figure 60. Active Pharmaceutical Ingredients (API) Market in France, 2015-2026, $ bn 90

Figure 61. Active Pharmaceutical Ingredients (API) Market in Germany, 2015-2026, $ bn 92

Figure 62. Active Pharmaceutical Ingredients (API) Market in Spain, 2015-2026, $ bn 94

Figure 63. Active Pharmaceutical Ingredients (API) Market in Italy, 2015-2026, $ bn 96

Figure 64. Active Pharmaceutical Ingredients (API) Market in Russia, 2015-2026, $ bn 98

Figure 65. Active Pharmaceutical Ingredients (API) Market in Rest of Europe, 2015-2026, $ bn 100

Figure 66. Growth Stage of Europe Active Pharmaceutical Ingredients (API) Industry over the Forecast Period 102



Enquire before buy

relatedReports

Purchase this Report
Please select buying option
Single User $2480
Multi User $3600
Enterprise $4800

Newsletters Signup

Sign up to Our Newsletter & get attractive Offers by subscribing to our newsletters.

Thank you for suscrbing!